ACE gene insertion/deletion polymorphism has a mild influence on the acute development of left ventricular dysfunction in patients with ST elevation myocardial infarction treated with primary PCI

BMC Cardiovascular Disorders

Volumn 10, Issue , 2010, Pages

  Parenica, Jiri ^a   Goldbergova, Monika P ^b   Kala, Petr ^a   Jarkovsky, Jiri ^b   Poloczek, Martin ^a   Manousek, Jan ^a   Prymusova, Krystyna ^a   Kubkova, Lenka ^a   Tomcikova, Daniela ^b   Toman, Ondrej ^a   Tesak, Martin ^a   Tomandl, Josef ^b   Vasku, Anna ^b   Spinar, Jindrich ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE;

ACUTE HEART FAILURE; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CAUCASIAN; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE SEVERITY; DNA POLYMORPHISM; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HEART LEFT VENTRICLE EJECTION TIME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FAILURE; HUMAN; INDEL MUTATION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; ACUTE DISEASE; GENE DELETION; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETICS; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; PHYSIOLOGY; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACUTE DISEASE; ANGIOPLASTY, BALLOON, CORONARY; FEMALE; GENE DELETION; HUMANS; MALE; MUTAGENESIS, INSERTIONAL; MYOCARDIAL INFARCTION; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; VENTRICULAR DYSFUNCTION, LEFT;

EID: 78650153658     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-10-60     Document Type: Article

References (28)

1. Yao S. Myocardial repair/remodeling following infarction: roles of local factors. Cardiovasc Res 2009, 81:482-490. 2639132, 19050008.
2. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. Journal of Clinical Investigation 1990, 86:1343-1346. 10.1172/JCI114844, 296868, 1976655.
3. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. American Journal of Human Genetics 1992, 51:197-205. 1682892, 1319114.
4. Danser AHJ, Schalekamp MADH, Bax WA, Van den Brink AM, Saxena PR, Riegger GAJ, et al. Angiotensin-converting enzyme in the human heart: Effect of the deletion/insertion polymorphism. Circulation 1995, 92:1387-1388.
5. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. The Lancet 1995, 345:669-682.
6. Gruppo Italiano per lo Studio della Soprawivenza nell'Infarto Miocardico GISSI-3: effects of lisiriopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. The Lancet 1994, 343:1115-1122. Gruppo Italiano per lo Studio della Soprawivenza nell'Infarto Miocardico.
7. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Lancet 1993, 342:821-828. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.
8. Borghi C, Cicero AFG, Ambrosioni E. Effects of early treatment with zofenopril in patients with myocardial infarction and metabolic syndrome: The SMILE Study. Vascular Health and Risk Management 2008, 4:665-671. 2515426, 18827916.
9. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown J, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction - Results of the survival and ventricular enlargement trial. New England Journal of Medicine 1992, 327:669-677. 10.1056/NEJM199209033271001, 1386652.
10. Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. New England Journal of Medicine 1995, 333:1670-1676.
11. Ertl G, Kloner RA, Alexander RW, Braunwald E. Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor. Circulation 1982, 65:40-48.
12. Palmer BR, Pilbrow AP, Yandle TG, Frampton CM, Richards AM, Nicholls MG, et al. Angiotensin-converting enzyme gene polymorphism interacts with left ventricular ejection fraction and brain natriuretic peptide levels to predict mortality after myocardial infarction. Journal of the American College of Cardiology 2003, 41:729-736. 10.1016/S0735-1097(02)02927-3, 12628714.
13. Ulgen MS, Ozturk O, Alan S, Kayrak M, Turan Y, Tekes S, et al. The relationship between angiotensin-converting enzyme (insertion/deletion) gene polymorphism and left ventricular remodeling in acute myocardial infarction. Coronary Artery Disease 2007, 18. 10.1097/MCA.0b013e328010a4c4, 17429286.
14. Nagashima J, Musha H, So T, Kunishima T, Nobuoka S, Murayama M. Effect of angiotensin-converting enzyme gene polymorphism on left ventricular remodeling after anteroseptal infarction. Clinical Cardiology 1999, 22:587-590. 10.1002/clc.4960220909, 10486698.
15. Ohmichi N, Iwai N, Maeda K, Shimoike H, Nakamura Y, Izumi M, et al. Genetic basis of left ventricular remodeling after myocardial infarction. International Journal of Cardiology 1996, 53:265-272. 10.1016/0167-5273(96)02562-4, 8793580.
16. Pinto YM, Van Gilst WH, Herre Kingma J, Schunkert H. Deletion-type allele of the angiotensin-converting enzyme gene is associated with progressive ventricular dilation after anterior myocardial infarction. Journal of the American College of Cardiology 1995, 25:1622-1626. 10.1016/0735-1097(95)00090-Q, 7759715.
17. Zee RYL, Solomon SD, Ajani UA, Pfeffer MA, Lindpaintner K. A prospective evaluation of the angiotensin-converting enzyme D/I polymorphism and left ventricular remodeling in the 'Healing and Early Afterload Reducing Therapy' Study. Clinical Genetics 2002, 61:21-25. 10.1034/j.1399-0004.2002.610104.x, 11903350.
18. Johnson A, Gong Y, Wang D, Langaee T, Shin J, Cooper-DeHof R, et al. Promoter polymorphism in ACE (Angiotensin I-converting enzyme) associated with clinical outcomes in hypertension. Clin Pharmacol Ther 2009, 85:36-44. 10.1038/clpt.2008.194, 2709290, 18946466.
19. Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Research 1992, 20:1433. 10.1093/nar/20.6.1433-a, 312213, 1313972.
20. Samani NJ, Thompson JR, O'Toole L, Channer K, Woods KL. A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation 1996, 94:708-712.
21. Yoshida M, Iwai N, Ohmichi N, Izumi M, Nakamura Y, Kinoshita M. D allele of the angiotensin-converting enzyme gene is a risk factor for secondary cardiac events after myocardial infarction. International Journal of Cardiology 1999, 70:119-125. 10.1016/S0167-5273(99)00064-9, 10454299.
22. Cambien F, Costerousse O, Tiret L, Poirier O, Lecerf L, Gonzales MF, et al. Plasma level and gene polymorphism of angiotensin-converting enzyme in relation to myocardial infarction. Circulation 1994, 90:669-676.
23. Gardemann A, Weiss T, Schwartz O, Eberbach A, Katz N, Hehrlein FW, et al. Gene polymorphism but not catalytic activity of angiotensin I-converting enzyme is associated with coronary artery disease and myocardial infarction in low-risk patients. Circulation 1995, 92:2796-2799.
24. Nakai K, Itoh C, Miura Y, Hotta K, Musha T, Itoh T, et al. Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with serum ACE concentration and increased risk for CAD in the Japanese. Circulation 1994, 90:2199-2202.
25. Cohn J, Tognoni G, . Valsartan Heart Failure Trial Investigators A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. New England Journal of Medicine 2001, 345:1667-1675. 10.1056/NEJMoa010713, 11759645, Valsartan Heart Failure Trial Investigators.
26. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: Experimental observations and clinical implications. Circulation 1990, 81:1161-1172.
27. Rott D, Behar S, Leor J, Hod H, Boyko V, Mandelzweig L, et al. Effect on survival of acute myocardial infarction in Killip classes II or III patients undergoing invasive coronary procedures. American Journal of Cardiology 2001, 88:618-623. 10.1016/S0002-9149(01)01802-1, 11564383.
28. Flaherty JD, Bax JJ, De Luca L, Rossi JS, Davidson CJ, Filippatos G, et al. Acute Heart Failure Syndromes in Patients With Coronary Artery Disease. Early Assessment and Treatment. Journal of the American College of Cardiology 2009, 53:254-263. 10.1016/j.jacc.2008.08.072, 19147042.